Evaluation of Anti- Antibodies in Hemodialysis Patients with Chronic Kidney Disease in Sari, Iran

Overview

Journal Nephrourol Mon

Publisher Brieflands

Specialty Nephrology

Date 2016 Nov 30

PMID 27896240

Citations 1

Authors

Seyyed Hosein Seyyedpour

Parvaneh Afshar

Ayoub Barzegarnejad

Shamsi Kalhori

Reza Agah

Affiliations

Soon will be listed here.

Abstract

Background: has worldwide distribution and is one of the most prevalent infectious agents in humans.

Objectives: The aim of this study was to determine the prevalence of anti- antibodies in hemodialysis patients with chronic kidney disease (CKD) in the hemodialysis unit of Fatemeh Zahra hospital at the Mazandaran University of Medical Sciences in Sari, Iran.

Methods: Seventy-three patients with CKD and 145 healthy volunteers were assessed for anti- (IgG, IgM, and IgA) antibodies using a conventional ELISA technique.

Results: The anti- IgG antibody was detected in 80.8% of the cases in the patient group, while 31.5% of the cases in the CKD patient group and 31.8% in the control group were found to be positive for the anti- IgA antibody. All the patients in the CKD group were negative for the anti- IgM antibody, although 2.76% of the healthy volunteers were found to be positive. The present study suggests that there was no significant difference between the hemodialysis patient group and the healthy volunteers.

Conclusions: The epidemiological data collected in this study could serve as a reference for future studies and may be useful in developing preventive and educational strategies, and consequently reducing healthcare expenditure.

Citing Articles

Sero-molecular prevalence of toxoplasmosis in hemodialysis and peritoneal dialysis patients in Markazi Province, Iran.

Sarmadian H, Shojapour M, Chegeni F, Tabatabaiefar M, Haghverdi F, Sarmadian R Trop Med Health. 2025; 53(1):7.

PMID: 39810270 PMC: 11730123. DOI: 10.1186/s41182-024-00676-3.

A systematic review and meta-analysis of the prevalence of toxoplasmosis in hemodialysis patients in Iran.

Foroutan M, Rostami A, Majidiani H, Riahi S, Khazaei S, Badri M Epidemiol Health. 2018; 40:e2018016.

PMID: 29748456 PMC: 6060338. DOI: 10.4178/epih.e2018016.

References

Bahia-Oliveira L, Jones J, Azevedo-Silva J, Alves C, Orefice F, Addiss D . Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg Infect Dis. 2003; 9(1):55-62. PMC: 2873742. DOI: 10.3201/eid0901.020160. View

Shin D, Cha D, Hua Q, Cha G, Lee Y . Seroprevalence of Toxoplasma gondii infection and characteristics of seropositive patients in general hospitals in Daejeon, Korea. Korean J Parasitol. 2009; 47(2):125-30. PMC: 2688793. DOI: 10.3347/kjp.2009.47.2.125. View

Spalding S, Amendoeira M, Klein C, Ribeiro L . Serological screening and toxoplasmosis exposure factors among pregnant women in South of Brazil. Rev Soc Bras Med Trop. 2005; 38(2):173-7. DOI: 10.1590/s0037-86822005000200009. View

Salahi-Moghaddam A, Hafizi A . A serological study on Toxoplasma gondii infection among people in south of Tehran, Iran. Korean J Parasitol. 2009; 47(1):61-3. PMC: 2655328. DOI: 10.3347/kjp.2009.47.1.61. View

Ebrahim Zadeh A, Bamedi T, Etemadi S, Shahrakipour M, Saryazdipour K . Toxoplasmosis as a complication of transfusion in hemodialysis patients. Iran J Ped Hematol Oncol. 2014; 4(1):22-5. PMC: 3980018. View

Nissapatorn V, Leong T, Lee R, Init-Ithoi , Ibrahim J, Yen T . Seroepidemiology of toxoplasmosis in renal patients. Southeast Asian J Trop Med Public Health. 2011; 42(2):237-47. View

Montoya J, Liesenfeld O . Toxoplasmosis. Lancet. 2004; 363(9425):1965-76. DOI: 10.1016/S0140-6736(04)16412-X. View

Ocak S, Duran N, Eskiocak A, Aytac H . Anti-Toxoplasma gondii antibodies in hemodialysis patients receiving long-term hemodialysis therapy in Turkey. Saudi Med J. 2005; 26(9):1378-82. View

Assmar M, Amirkhani A, Piazak N, Hovanesian A, Kooloobandi A, Etessami R . [Toxoplasmosis in Iran. Results of a seroepidemiological study]. Bull Soc Pathol Exot. 1997; 90(1):19-21. View

10.

Kamani J, Mani A, Egwu G, Kumshe H . Seroprevalence of human infection with Toxoplasma gondii and the associated risk factors, in Maiduguri, Borno state, Nigeria. Ann Trop Med Parasitol. 2009; 103(4):317-21. DOI: 10.1179/136485909X435094. View

11.

Ghorbani M, Edrissian G, Afshar A . Serological survey of human toxoplasmosis in mountainous regions of the north-west and south-west parts of Iran (1976-77). Trans R Soc Trop Med Hyg. 1981; 75(1):38-40. DOI: 10.1016/0035-9203(81)90011-0. View

12.

Yazar S, Demirtas F, Yalcin S, Yaman O, Tokgoz B, Utas C . Anti-Toxoplasma gondii antibodies in haemodialysis patients with chronic renal failure. Yonsei Med J. 2003; 44(2):288-92. DOI: 10.3349/ymj.2003.44.2.288. View

13.

Tenter A, Heckeroth A, Weiss L . Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000; 30(12-13):1217-58. PMC: 3109627. DOI: 10.1016/s0020-7519(00)00124-7. View

14.

Sensini A . Toxoplasma gondii infection in pregnancy: opportunities and pitfalls of serological diagnosis. Clin Microbiol Infect. 2006; 12(6):504-12. DOI: 10.1111/j.1469-0691.2006.01444.x. View

15.

Aufy S, Mahgoub A, Saadi M, Elmallawany M . Serological detection of Toxoplasma gondii in chronic renal failure patients and renal transplant recipients. J Egypt Soc Parasitol. 2010; 39(3):943-50. View

16.

Chen X, Tan F . [Toxoplasma gondii: past, present and future]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2010; 27(5):426-31. View

17.

Alvarado-Esquivel C, Liesenfeld O, Torres-Castorena A, Estrada-Martinez S, Urbina-Alvarez J, Ramos-de la Rocha M . Seroepidemiology of Toxoplasma gondii infection in patients with vision and hearing impairments, cancer, HIV, or undergoing hemodialysis in Durango, Mexico. J Parasitol. 2010; 96(3):505-8. DOI: 10.1645/GE-2378.1. View

18.

Ghorbani M, Edrissian G, Assad N . Serological survey of toxoplasmosis in the northern part of Iran, using indirect fluorescent antibody technique. Trans R Soc Trop Med Hyg. 1978; 72(4):369-71. DOI: 10.1016/0035-9203(78)90129-3. View